AstraZeneca Pharmaceuticals LP will be able to limit the discounts it must provide in a federal drug-pricing program aimed toward low-income individuals following a federal court order, capping off a lawsuit against the Health and Human Services Department over actions taken during both the Trump and Biden administrations.
The Biden administration’s HHS exceeded its legal authority when it used a letter to demand AstraZeneca honor discounts through the government’s 340B program, the U.S. District Court for the District of Delaware said March 11. The drugmaker had been limiting shipments of discounted products to for-profit pharmacies that dispensed them on ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.